biobanking, biomarker, diganostics, ethics · 12/16/2019 · molecular cancer diagnostics ......
Post on 12-Oct-2020
3 Views
Preview:
TRANSCRIPT
Christian Röder, PhDInstitute for Experimental Cancer Research and
Centralized Biomaterial Bank P2N of the Medical Faculty, CAU
Biomarker for personalized medicine
biobanking, biomarker, diganostics, ethics
Outline of Lecture / Seminar
Lecture Dec-16-2019
• Biobanking as a Tool for Research / Biobanks / Aims
• Standards in Biobanking: Quality management, Ethics
• Biomarkers: Types / Utilization / Diagnostics / Limitations
Seminar
• Paper by Andrew Woolston et.al., Cancer Cell 36, 2019
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
Learning Objectives
• define / describe the term biobank• name the requirements of high quality biobanking• name the major topics of a patient informed consent• biomarkers: name the characteristics of goodbiomarkers / diagnostic tests
• describe the different types and use of biomarkers aswell as their limitations
Time Magazine March 23, 2009:
• Biobanks are mentioned as1 of 10 ideas changing theworld right now
Atmosphere of awakening in geneticsand genomics with human clinicalspecimen
• 1st human genome sequence (2001)after 10 yrs at costs of 3 billion $
• Next Gen. Sequencing (NGS) (2005)• 1000 genomes project (2008)• 100,000 genomes project (UK, 2012)• US Precision Medicine Initiative
(2015), 1 Million Genome• EU 1+Million Genomes Initiativesigned on 10.4.2018 by meanwhile20 EU member states
Biomaterial Banks
Human Genome Sequencing
https://www.genome.gov/sequencingcostsdata/Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP)
What is a Biobank ?
Biobanks [are] collections of samples of human body substances[...], which are linked or may be linked to personal data andinformation of the donors. Biobanks simultaneously share
characteristics of a collection of specimen and data.
German National Ethics Council Statement (Nationaler Ethikrat, 2006)
www.ukbiobank.ac.uk
What is a Biobank ?
• Any collection of biospecimens or genetic and othermaterial thereof with and without associated data
• Retained for sharing and/or future use
• with or without identifying (donor) information
• de facto – collectionsamples kept in lab freezers on occasion: accidental bank
• de jure – biorepositorydesigned for storage and sharing, ethics board-approved, scope, governance, consent forms, sample catalog, use & access policy (board)
What is a Biobank ?
collection on occasion biorepository
Profile and Requirements of a Biobank ?
• sufficient (large) scale of collections• multiple aliquots of samples for multiple use• long-term storage• flexible scientific questions and future analyses,
driven by future research insights / requirements• connection of samples and data (research-, medical-
and follow up-)• ethics („ELSI“) regulations: data protection and
„Informed Consent“ of donors• quality management (SOPs)• use and access regulations
Standard Operating ProcedureGovernance / Quality Management
Informed Consent
Informed Consent
Informed ConsentSynopsis
• Easy to understand outline of the project, aims andcollected materials; broad (general) scientific question
• Information about combined sample and data collectionwith pseudonymization
• No direct benefit for the donor (neither medical norfinancial)
• Information about any reporting of individual researchdata (not intended in Kiel/P2N)
• Right of donors to withdraw their consent (impossiblein case of anonymization)
• Long-term storage of specimen
Biobanks - Advantages
• large and well characterized pre-existing collectionsfor investigations of weak or moderate biologigal effects
• no recruiting phase for donorsallows faster processing of scientific questions
• availability of quality-controlled reference materialsfor validation of in-vitro or per-clinical results
• access for the broad scientific community tovaluable human materials for reseach
• establishment of scientific and ethical standards in patient-based research
Biobanks - Disadvantages
• long-term determinationwith regard to donor cohorts, materials, preparations
• unflexible planning for requirements and scientificconceptsdue to SOPs and clinical workflows
• long-term commitment for budgets and lab ressources(rooms, staff, equipment and consumables)
• low scientific impact / „broad effects“in terms of „scientific output parameters“(papers, grants, graduate projects)
Different types of biobanksHuman biobanks
• banks of organs and tissues for therapy / transplantation- blood bank- organ bank (whole organs, heart valves, cornea)
• research-related biobanks- ethnical cohorts, twin-biobanks, ....- disease-oriented / clinical / epidemiological biobanks- population (prospective) biobanks↳ study of common, complex, or rare diseases over long time
Population-based BiobanksGerman National Cohort (NAKO Gesundheitsstudie)
https://nako.de
• 18 study centers• 200.000 randomly chosencitzens (age 20-69)
• detailed medical examinationand anamnesis: medical data
• 28 mill. biomaterial samples• follow-up examination andmultiple follow-up anamnesis
• time span: 2013 - 2042
Population-based BiobanksGerman National Cohort (NAKO Gesundheitsstudie)
https://nako.de
Year 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 ...........................................2042
base examination
follow up examination
active and passive follow up(every 2-3 yrs: questionaires, registries)
pilotstudy
utilization for research studies
PopGen 2.0 Network
Governance
ELSI
Governance
Institute ofPathology
Clinic for Neuro-Pediatrics Univ. Lung Center North
Clinic for Neurosurgery
Clinic for General SurgeryInst. of Pathology
Inst for Exp. Cancer Research
Institute for Epidemiology
Institute ofPharmacology
PopGen 2.0 Network: 10 partner BMBsBMBF grant 2011-2016 (5 Mio. €)
BMBEnzephalitis
BMBIKMB
BMBGyn
PopGen 2.0 Network
• Central management of patient consents; implementation of a „broad
consent“ for the use for research of residual clinical materials
• Central use & access structures for the utilization of samples and data
• P2N-wide LIMS / data- and sample-management software with central
data base hosting, maintenance and IT support
• Adaption and/or implementation of harmonized data and privacy
protection concepts
• Central quality management, harmonized SOPs,
perspective: ISO 9001 certification
• P2N-wide DNA preparation and storage facility
• Perspective: Harmonization and Cooperation with the new UKSH-CAU
medicine-informatics department
Aims
Biomaterial Storage Unit PopGen / P2N
Center of Molecular Biosciences (CMB) Kiel
LiCONiC walk-in repository-80�sample storage in the CMB
Biomaterial Bank PopGen
Stroke
Parodontitis
Gall stonesSarcoidosis
Morbus Crohn
ParkinsonDepression
PsoriasisPemphigus
Colitis ulcerosa
Biomaterial Bank for different diseases
> 80.000 participants> 120.000 biosamples> 150 clinical partner> 250 collaborations>> 200 high-ranked papesColorectal Cancer
Epilepsy
TuberculosisCardio-Vascular Diseases
Patient
Information
writtenconsent
Tumor ResectionClinic for General Surgery, Visceral, Thoracic,
Transplantation and Pediatric Surgery
Data
LIMS / Database ProWebDBCentraXX
Biomaterial Bank CCC
Blood, Serum, Plasma Cryo-Bone Marrow, Lavage Tissue
Biobank LaboratoryInst. f. Experimental Cancer Research
tumor & peritumoral non-malignant, IBD
Institute of Pathology
Data•Sample Logistics•Patient•Clinic•Pathology•Therapy•Research•Follow up
LIMS / Database Inst. f. PathologyCentraXX
Biomaterial Bank Patho
FFPE-,Cryo-Tissue
Oncological Biobank – BMB-CCCStructure and Procedures
Liquid Tissue
Molecular Cancer DiagnosticsGoing to improve medicine
Cancerpredisposition
Cancer detection /Early detection
Therapy /Drug selection
Follow-upRecurrence monitoring
Individualized therapy Which diseaseIs a patient atrisk for?
Has a patient a disease?
Which drugs should be prescribed?
Has the disease returned?Diagnosis Confirmation
and Prognosis
What is the likely course of a disease?
Key Questions
Biobank Materials are needed to defineBiomarkers for Personalized Medicine
Blood: Serum / Plasma / CellsPancreatic JuiceUrine / StoolSalivaBiopsy / Tissue / Cytology
Protein (Glycoproteins)DNA (SNPs/point mutations, methylated DNA)RNA (mRNA, miRNA, ncRNA, circRNA)Metabolites
Circulating & Disseminated Tumor Cells (CTC / DTC)Platelets
A good detection system should have 4 qualities:
ü Sensitivityü Specificityü Simplicity and Cost-Effectivenessü Robustness
Sensitivity means that the test must be able to detect very small amounts of target in case of a disease even in the presence of other molecules. (“positivity in disease”)
Specificity: the test yields a positive result for the target molecule and in the case of the disease only. (“negativity in health”)
Simplicity / Cost Limitations / Robustness: the test must be able to run efficiently and inexpensively on a routine basis and should run under various laboratory conditions. Benchmarking, “Ringversuche”
Biomarker DiagnosticsCharacteristics of a diagnostic test system
Diagnostic Biomarkers specifically indicate a particular disease
Prognostic Biomarkers predict the course of a diseasein untreated patients („high vs. low risk“)
Biomarker-Definitions
Molecular Cancer Diagnostics
• Classical cancer pathology: investigation of tissue biopsies, surgery resectates, lymph node pathology: TNM classification
Molecular Cancer Diagnostics
• Classical cancer pathology: investigation of tissue biopsies, surgery resectates, lymph node pathology: TNM classification
• „The TNM classification of the UICC gives a solid basis fortumor staging. It‘s still the most important instrument fortherapy decisions.• Up to now, the TNM classification was never
outperformed by any other prognosticbiomarker“
(C. Röcken, FORUM 2016 · 31:406–411)
Molecular Cancer Diagnostics
www.mindsofmalady.com
• Classical cancer pathology: investigation of tissue biopsies, surgery resectates, lymph node pathology: TNM classification
• Molecular pathology: genetic and phenotypic markers
• Liquid biopsy:• Cytological investigation of blood
- cytogenetics (karyotypes, FISH)- molecular markers / circulating tumor cells• Identification of virus infections• Analysis of cerebrospinal fluid• Analysis of cancer biomarkers in blood
(serum/plasma)
Tumor&Marker& Elevated&in:& Comment&CA1979& Pancreas(,*Gastric(,*
Cholangio(Ca.*carbohydrate(epitope*on*ganglioside*or*mucin*
CEA& Colon(,*Rectum(,*Gastric(,*Lung(,*Breast(Ca.*
membran*glycoprotein,*=CEACam*
Colorectal Cancer
Diagnostic Biomarkers for systemic Cancer Detection in Liquid Biopsies
Tumor-associated Antigens / Serum Markerin gastrointestinal Cancer
• some are long established
• not very sensitive nor specific
provide information on the likely prognosis or course ofthe disease in an untreated individual
• studies problematic in oncology, since most patientsreceive (besides surgery) some adjuvant therapy
• however, clinically important ’prognostic‘ studiescomprise early-stage tumors that are not treated byadjuvant therapy (e.g. stage I/II colorectal cancer)...
Prognostic Biomarkers
Prognostic Biomarkers
Kaplan-Meier-survival analysis
Log-Rank testP< 0.05 = significant
differencein survival
Colorectal carcinoma (CRC)
• many patients suffer from recurent disease- cancer patients mostly die from metastases or relapse
• prognostic markers are needed to selectotherwise untreated patients for adjuvant therapy
post-surgicalchemo-therapy
5-yr survival rate
Prognostic Biomarkers for Cancer Cell Detection in Liquid Biopsies
Schroeder et al.Nature Reviews Cancer 2012
Keratin20 (CK20)-nested RT-PCR
Circulating Tumor Cells (CTC)
„Rare Event Detection�
CK20 qRT-PCR
Detection of CTC / DTC of solid Tumors
MNC fraction+ tumor cells
APAAP complex
„Rare Event Detection� 10ml blood:100 million leukocytes
Enrichment: 50 billion erythrocytes• Ficoll cushion or• positive selection• negative selection
BiobankLab
2 x 106 MNC
• 10 ml venous blood
cytokeratin stainingwith mAB A45-B/B3
Ficoll
plasma, platelets
erythrocytes, granulocytes
Detection
biological properties ?
Ficoll
40 min, 400 xg
blood diluted 1:3 (RPMI1640)
Pan-keratin cytology
Patients: Liquid Biopsy
CK-20 RT-PCR
Kaplan-Meier-Analysis
Stage I+IIP<0.001 (log Rank)n=209
CK20 –
CK20 +
[months][cummulativesurvival]
• pioneering registry: www.genetests.org• Information resource e.g. for healthcare providers• Located at the University of Washington, Seattle• was funded by the National Institutes of Health• phased out 2013 from NIH that now runs own registry
Biomarker Registries
Biomarker (Genetic Testing) Registries
Prognostic Genetic Test Systems
Genes:BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, MEN1, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, TP53, VHL, NTRK1, RET, APC
Method:Next Generation Sequencing
Material:6-9 ml blood or 5 µg DNA
Prognostic Genetic Test Systems
Prognostic Genetic Test Systems
Mar 27, 2013
• 5-10% of hereditary breast cancerwith autosomal dominant inheritance
• BRCA1 is affected with very high frequency
• woman with inherited germ line mutationstatistically develop breast cancer- 20 yrs earlier- 80-90% incidence
Prognostic Genetic Test Systems
Mar 27, 2013Mar 10, 2016
Diagnostic Biomarkers specifically indicate a particular disease
Prognostic Biomarkers predict the course of a diseasein untreated patients („high vs. low risk“)
Predictive Biomarkers predict the probability of a therapy responsein a patient
Biomarker-Definitions
A ‘companion diagnostic’ is a test or assay that detects a predictivebiomarker, thereby allowing classification of patients (tumors) intoresponders and non-responders
Synonyms: ‘predictive diagnostic’, ‘precision diagnostic’, ‘theranostic’,‘advanced personalized diagnostic’
Targeted Tumor TherapyTumor-specific aberrations
• Overexpression ofoncogenes
• Overexpression of tyrosinekinases e.g. Her2
• Expression of fusion proteinse.g. Bcr-Abl
• Mutations / SNPse.g. ras-family, raf-family
• Loss of tumorsuppressor gene(function), e.g. TP53
Targeted Tumor Therapy
identify subgroups of patients who are most likelyto respond to a given therapy
• predictive markers are the basis of individualizedtreatment
Predictive Biomarkers
Examples (predictive markers in tumor tissue):• estrogen- / progesterone-receptor status
in breast cancer for hormone therapy
• HER2-status for Herceptin treatment
• KRAS mutation or wildtype for Anti-EGFR therapy↳ Molecular Pathology Precision Oncology
• Cetuximab („Erbitux“) approval in 2003 (US) and 2004 (EU)
• Approval for •CRC (EGFR+, KRAS-wt) in combination withchemotherapy and •squamous cell head & neck cancer in combination with radiation or chemotherapy
• Well known side effects (>20%) e.g. ulcerous skin inflammation
• Increased survival in responders by months
• Costs: 14-day cycle: 5000 €; standard: 12 cycles = 60.000 €
Anti-EGFR Tumor TherapyCetuximab / Erbitux
Gonzalez de Castro et al., Br J Cancer 107, 345 (2012):
• Patients with colorectal tumors containing activating KRAS mutations do not benefit from therapy with cetuximab and panitumumab.
• KRAS mutation status is a key determinant of response to anti-EGFR therapy.
• The European Medicines Agency states that anti-EGFR therapy is only indicated in patients with wild-type KRAS tumors.
• The US Food and Drug Administration states that such treatment is not recommended in tumors with mutations in codons 12 and 13 of KRAS.
• The European Society for Medical Oncology recommends that tumours are KRAS wild type, without naming specific mutations.
Anti-EGFR Tumor TherapyDetection of KRAS point mutations
K-Ras wildtype as predictivebiomarker for Anti-EGFR (e.g. Cetuximab) therapy
• Analysis of pointmutations in tumor tissue:
Cetuximab / Erbitux
Anti-EGFR Tumor TherapyDetection of KRAS point mutations
Anti-EGFR Tumor TherapyDetection of KRAS point mutations
K-Ras wildtype as predictivebiomarker for Anti-EGFR (e.g. Cetuximab) therapy
?
K-Ras wildtype as predictivebiomarker for Anti-EGFR (e.g. Cetuximab) therapy
• Analysis of pointmutations in tumor tissue:
- resected specimen maybe heterognous: e.g. stroma-rich:selection by dissection
- realtime PCR orsequencing
Cetuximab / Erbitux
Anti-EGFR Tumor TherapyDetection of KRAS point mutations
CUSA: Cavitron UltrasonicSurgical Aspirator
Cancers 2013, 5, 357-371
Antigen HeterogeneityIn tissue fragments after ultrasonic aspiration
Tsiatis et al., J Mol Diagn 12:425(2010)
Arrow = Detection Limit
Pyro-Sequencing: 5% mut.Sanger Seq.: 18% allelesMelting Curve: 18%(realtime PCR)
PS
SS
MC
Detection of KRAS point mutationsSensitivity of techniques
Detection of KRAS point mutationsCOBAS KRAS Mutation Analysis Test (Roche)
Cree et al., Biomol Detect Quantification 8:29 (2016)
Lee et al., Virchow‘s Arch 460:141(2012)
Calculateconcentrationfrom numberof droplets
FAM
am
plitu
de
VIC amplitude
Patient plasma Sample ispartitionedinto 20,000 droplets
Measurefluorescenceintensity in eachdroplet
Run PCR cycles in all dropletssimultaneously
1. Partition 2. Cycle 3. Read
Digital PCR
top related